MimiVax
- Biotech or pharma, therapeutic R&D
MimiVax is developing immunotherapy for survivin-expressing cancers. Strategic investment, M&A, seeking out-license for SurVaxM (lead) & MV2C2 (preclinical) pipeline agents.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}